Suspension of trading
Biotest AG Stock Deutsche Boerse AG
Stocks
BIO3
DE0005227235
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.20 EUR | +1.34% |
|
+1.34% | +13.53% |
| 06-15 | Biotest GmbH & Co. KGaA announces Annual dividend, payable on July 24, 2026 | CI |
| 03-25 | Biotest GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 1.31B 1.49B 1.21B 1.12B 2.1B 144B 2.14B 14.4B 5.65B 70.28B 5.61B 5.49B 242B | P/E 2024 * |
-
| P/E 2025 | -17.7x |
|---|---|---|---|---|---|
| Enterprise Value | 2.05B 2.34B 1.89B 1.75B 3.29B 225B 3.35B 22.57B 8.86B 110B 8.8B 8.61B 379B | EV / Sales 2024 * |
-
| EV / Sales 2025 | 3.36x |
| Free-Float |
28.77% | Yield 2024 * |
-
| Yield 2025 | 0.13% |
| 1 week | +1.34% | ||
| 1 month | +1.34% | ||
| 3 months | +4.50% | ||
| 6 months | +16.15% | ||
| Current year | +13.53% |
| 1 week | 29.6 |  | 30.2 |
| 1 month | 29.6 | | 30.2 |
| 3 years | 23 | | 36.3 |
| 5 years | 19.85 | | 43.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jörg Schüttrumpf
CEO | Chief Executive Officer | 52 | 2025-05-27 |
Oliver Hein
CMP | Compliance Officer | - | 2016-12-31 |
Christian Polus
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 2022-05-04 | |
Dirk Schuck
BRD | Director/Board Member | 47 | 2022-04-05 |
David Ian Bell
BRD | Director/Board Member | 72 | 2022-05-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.34% | +1.34% | +14.83% | -15.17% | 1.49B | |
| +1.70% | +0.36% | +21.41% | -7.80% | 66.75B | |
| +1.38% | -5.23% | +38.08% | +194.04% | 50.65B | |
| +1.10% | +38.30% | +38.30% | +38.30% | 42.55B | |
| -0.98% | -1.79% | -49.61% | -53.35% | 41.15B | |
| +1.92% | -2.59% | +53.08% | -29.89% | 28.34B | |
| -0.87% | -9.11% | +112.41% | -45.29% | 26.76B | |
| +0.16% | -1.94% | +68.47% | +88.24% | 22.95B | |
| +7.77% | +11.30% | +18.35% | +199.08% | 20B | |
| -2.01% | +5.43% | +75.83% | +157.74% | 16.48B | |
| Average | +1.15% | -2.38% | +39.12% | +52.59% | 35.07B | |
| Weighted average by Cap. | +1.13% | -2.97% | +33.64% | +48.14% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 726M 831M 671M 620M 1.17B 79.82B 1.19B 8.01B 3.14B 39.08B 3.12B 3.05B 135B | 649M 743M 600M 554M 1.04B 71.32B 1.06B 7.15B 2.81B 34.92B 2.79B 2.73B 120B |
| Net income | 26.4M 30.21M 24.4M 22.55M 42.46M 2.9B 43.23M 291M 114M 1.42B 113M 111M 4.89B | -70.7M -80.9M -65.36M -60.38M -114M -7.77B -116M -779M -306M -3.81B -304M -297M -13.1B |
| Net Debt | 552M 632M 511M 472M 888M 60.71B 904M 6.09B 2.39B 29.73B 2.37B 2.32B 102B | 742M 849M 686M 634M 1.19B 81.53B 1.21B 8.18B 3.21B 39.92B 3.19B 3.12B 137B |
Employees
-
Sector
Pharmaceuticals
Calendar
07-22 -
Ex-dividend date - 0.04 EUR
Net sales - Rate of surprise
- Stock Market
- Stocks
- BIO0 Stock
- BIO3 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
